Loading ...

Srinath Sanda, MD

Immune Tolerance Network

Director, Clinical and Translational Medicine

Assessment Group

Type 1 Diabetes

ssanda@immunetolerance.org

Work:

415-353-4414

Mobile:

415-854-7839

Address:

Immune Tolerance Network

Committees:

,

Studies:

ITN027AI

-

Autoimmunity-blocking Antibody for Tolerance in Recently Diagnosed Type 1 Diabetes

ITN028AI

-

Study of Antithymocyte Globulin for Treatment of New-onset T1DM

ITN041AI

-

A Research Trial of Aralast in New Onset Diabetes

ITN043AD

-

Long-Term Effects of Sublingual Grass Therapy

ITN045AI

-

Inducing Remission in Type 1 Diabetes With Alefacept

ITN050AD

-

Peanut Oral Immunotherapy in Children

ITN057AD

-

Anti-TSLP (AMG 157) Plus Antigen-Specific Immunotherapy for Induction of Tolerance in Individuals With Cat Allergy

ITN058AI

-

Tocilizumab (TCZ) in New-onset Type 1 Diabetes

ITN061AD

-

Cat Pilot Study - Environmental Exposure Chamber (EEC) vs. Nasal Allergen Challenge (NAC)

ITN065AI

-

TCZ in Pediatric New-onset T1D

ITN066AI

-

Type 1 Diabetes Extension Study

ITN072AD

-

GLA-AF plus antigen-specific immunotherapy in individuals with seasonal allergic rhinitis

ITN078AI

-

Immunotherapy to Preserve Residual Insulin in New-onset Type One Diabetes

ITN095AI

-

Siplizumab in T1DM

ITN819AI

-

Type 1 Diabetes Immunotherapy Using Polyclonal Tregs

ITN826AI

-

Pilot Clinical Trial of Ustekinumab in Patients With New-onset T1D

ITN827AI

-

Tregs and IL-2 in Type 1 Diabetes

Bio:

Admin Links

Shortcuts

ITN Documents

Links